Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LOBAPLATIN for Lung neoplasm malignant: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 19 adverse event reports in the FDA FAERS database where LOBAPLATIN was used for Lung neoplasm malignant.

Most Reported Side Effects for LOBAPLATIN

Side Effect Reports % Deaths Hosp.
Myelosuppression 84 42.2% 1 50
White blood cell count decreased 21 10.6% 0 12
Platelet count decreased 17 8.5% 1 11
Off label use 15 7.5% 1 8
Nausea 14 7.0% 1 5
Neutrophil count decreased 14 7.0% 0 7
Bone marrow failure 12 6.0% 0 5
Vomiting 11 5.5% 1 5
Hepatic function abnormal 10 5.0% 0 1
Rash 10 5.0% 0 3
Asthenia 9 4.5% 1 3
Diarrhoea 9 4.5% 2 3
Anaemia 8 4.0% 0 2
Gastrointestinal disorder 8 4.0% 0 0
Pyrexia 8 4.0% 0 6

Other Indications for LOBAPLATIN

Hepatocellular carcinoma (16) Breast cancer (12) Ovarian cancer (12) Lung adenocarcinoma (11) Oesophageal carcinoma (10) Adenocarcinoma (9) Chemotherapy (7) Oesophageal squamous cell carcinoma (5) Serous cystadenocarcinoma ovary (5) Small cell lung cancer (5)

Other Drugs Used for Lung neoplasm malignant

ERLOTINIB (9,207) OSIMERTINIB (4,754) NIVOLUMAB (4,197) PEMBROLIZUMAB (3,575) CARBOPLATIN (3,487) ALECTINIB (2,932) PEMETREXED (2,422) CRIZOTINIB (1,949) BEVACIZUMAB (1,810) PACLITAXEL (1,747)

Related Pages

LOBAPLATIN Full Profile All Lung neoplasm malignant Drugs LOBAPLATIN Demographics LOBAPLATIN Timeline